Jasper Therapeutics (JSPR) H.C. Wainwright 28th Annual Global Investment Conference summary

Strategic developments and pipeline overview

• Completed a merger with Kira Pharmaceuticals, creating a diversified immunology pipeline with two clinical-stage assets and a third nearing clinical entry.

• Lead asset vensobafusp (KP-104) is a dual inhibitor of the complement cascade, showing positive phase II results in PNH and advancing toward FDA discussions for approval.

• Briquilimab, targeting the KIT receptor, is being developed for SCID transplant patients and has orphan and rare pediatric disease designations, with a pre-BLA meeting planned next year.

• KP-701, a bispecific antibody targeting CD79B and CD32B, aims to induce B cell anergy with a potentially improved safety profile over depletion therapies.

• Out-licensed a C5 long-acting program to Mirador, with additional assets in earlier development stages.

Clinical data and competitive positioning

• Vensobafusp phase II in PNH showed all patients had ≥2 g/dL hemoglobin increase, 89% normalized hemoglobin, and 100% transfusion-free status.

• Phase III trials for vensobafusp are planned, targeting both naive and C5-experienced PNH patients, with FDA meetings expected in the first half of next year.

• Renal basket study for vensobafusp in IgA nephropathy is ongoing, with interim data expected later this year and plans to expand to C3G, FSGS, and other indications.

• KP-701 is nearing IND/CTA filing, with plans to benchmark against other CD79BxCD32B agents in development.

• Briquilimab's future in CSU depends on competitive phase III data and differentiation from other KIT inhibitors.

Financial position and upcoming milestones

• Post-merger, the company is funded with approximately $140 million, supporting operations into late 2028.

• Shareholder vote for preferred-to-common conversion is scheduled for early November, finalizing the merger process.

• Key milestones in the next 12 months include vensobafusp proof-of-concept data in IgA nephropathy, briquilimab analysis in SCID, expanded renal data, first KP-701 data, and FDA feedback on key programs.